PRESS RELEASE 29-OCT-2025_OptiCell Solutions
We are proud to announce our new research collaboration with Karolinska Institutet.
Through a two-year agreement, OptiCell Solutions will supply high-quality apheresis generated cell material to support the development and validation of cell and gene therapy manufacturing processes, including gene modification for immunotherapy.
This collaboration addresses a key challenge in advanced therapy development: ensuring reliable and timely access to high-quality starting material. Together, we aim to accelerate research and help advance new treatment options for patients with cancer and autoimmune diseases.
We look forward to the journey ahead.
#OptiCellSolutions #KarolinskaInstitutet #ATMP #CellTherapy #GeneTherapy #Immunotherapy #Apheresis #GMP #TranslationalResearch #PrecisionMedicine #Biotech #LifeScience #SwedenBio
OptiCell Solutions
By Car: Hälsovägen 7, Elevator A, Floor 7
Commuter Train/Buss: Blickagången 6A, Elevator A, Floor 7
141 57 Huddinge, Sweden
OptiCell Solutions
Novum Labs
Hälsovägen 7, Floor 5, Elevator E, Box 1
141 57 Huddinge, Sweden
Information
GCP - ICH guideline for good clinical practice
Audits from Medicines Agency, IVO, Biotech companies, Healthcare sector, The Pharmacy
Board of Directors
Please visit www.allabolag.se
Annual Report
Please visit www.allabolag.se
IVO Register
Owners
CliniQnect AB, Jarmo Henriksson, Peter Rybäck, Patrik Åvestrand
Copyright © 2024-25 OptiCell Solutions AB. All rights reserved.